ArticleClinical nuclear medicine2016
Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer.
Article in Clinical nuclear medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma: A systematic review and meta-analysis.Medicine · 2017Pooled it
- [Molecular imaging and biology · 2021Trial
- First-in-human EphA2-targeting PET imaging with the bicyclic radiotracer [European journal of nuclear medicine and molecular imaging · 2026Article
- Realistic PET image synthesis from MRI for automated inference of brain atrophy and Alzheimer's.iScience · 2026Article
- A pilot study of nectin-4-targeted radioligand [European journal of nuclear medicine and molecular imaging · 2026Article
- Molecular Imaging: Unveiling Metabolic Abnormalities in Pancreatic Cancer.International journal of molecular sciences · 2025Review
- MRI2PET: Realistic PET Image Synthesis from MRI for Automated Inference of Brain Atrophy and Alzheimer's.medRxiv : the preprint server for health sciences · 2025Article
- TMEM105 modulates disulfidptosis and tumor growth in pancreatic cancer via the β-catenin-c-MYC-GLUT1 axis.International journal of biological sciences · 2025Article
- Optimized FDG-PET/MRI protocol reveals metabolic predictors of long-term survival in pancreatic cancer patients.Frontiers in oncology · 2024Article
- Advances in pre-treatment evaluation of pancreatic ductal adenocarcinoma: a narrative review.Journal of gastrointestinal oncology · 2023Review
- Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?International journal of molecular sciences · 2021Review
- Can Spectral Power Be Used as a Candidate Seizure Marker of the Periodic Discharges Pattern?Frontiers in neurology · 2021Article
- A Novel Validated Recurrence Stratification System Based onFrontiers in oncology · 2021Article
- Venous thromboembolism detected by FDG-PET/CT in cancer patients: a common, yet life-threatening observation.American journal of nuclear medicine and molecular imaging · 2021Article
- Value of PretreatmentFrontiers in oncology · 2020Article
- Article
- 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2018Article
- Qualification of National Cancer Institute-Designated Cancer Centers for Quantitative PET/CT Imaging in Clinical Trials.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Review
- Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma.International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
purposeMetabolic activity, as defined by F-FDG uptake on PET, is a prognostic marker for multiple malignancies; however, no study has examined the prognostic value of imaging with FDG PET in stage I and II pancreatic cancer. We examined the value of PET FDG uptake in early-stage pancreatic cancer patients.
methodsWe identified patients with early-stage pancreatic cancer (I-II) who had FDG PET scan performed as part of their preoperative evaluation. The patients were divided into either high or low FDG uptake according to the median primary tumor standard uptake value (SUVmax). Our primary end points were overall survival (OS) and recurrence-free survival (RFS). Kaplan-Meier estimate was used for survival analysis. Pathologic data were compared using the Fisher exact and χ tests.
resultsOne hundred five patients were identified: 51 patients with low FDG uptake and 54 patients with high FDG uptake. Eighty-five patients (81%) had PET avid tumors, whereas 20 (19%) patients did not. High FDG uptake correlated with pathologic stage (P = 0.012). Patients with low FDG uptake had significantly better median OS than patients with high FDG uptake (28 vs. 16 months; P = 0.036). Patients with low-FDG uptake had significantly longer median RFS than patients with high FDG uptake (14 vs. 12 months; P = 0.049).
conclusionsLow FDG uptake in PET scans in patients with stage I and II pancreatic cancer correlates with improved OS and RFS. This supports the concept that glucose metabolic pathways are important in pancreatic cancer biology and that PET scan activity can be used as a prognostic biomarker after pancreatectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.